Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 429

1.

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase 1b/2 PCYC-1102 Study.

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger J, Blum KA, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien S.

Clin Cancer Res. 2020 Mar 24. pii: clincanres.2856.2019. doi: 10.1158/1078-0432.CCR-19-2856. [Epub ahead of print]

2.

Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia.

Sasaki K, Kantarjian H, Wierda W, Ravandi F, Daver N, Burger J, DiNardo CD, Jain N, Short NJ, Estrov Z, Konopleva M, Ohanian M, Garcia-Manero G, Kadia T, Alvarado Y, Yilmaz M, Pierce S, Garris R, Cortes J, O'Brien S, Ingram A, Jabbour E.

Am J Hematol. 2020 Mar 14. doi: 10.1002/ajh.25784. [Epub ahead of print]

PMID:
32170867
3.

How I Manage CLL with Venetoclax-Based Treatments.

Wierda WG, Tambaro FP.

Blood. 2020 Feb 19. pii: blood.2019002841. doi: 10.1182/blood.2019002841. [Epub ahead of print]

PMID:
32076705
4.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.

Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H.

J Natl Compr Canc Netw. 2020 Feb;18(2):185-217. doi: 10.6004/jnccn.2020.0006.

PMID:
32023533
5.

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.

Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K.

N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.

PMID:
32023374
6.

Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations.

Tambaro FP, Wierda WG.

Lancet Haematol. 2020 Feb;7(2):e168-e176. doi: 10.1016/S2352-3026(19)30253-4. Review.

PMID:
32004486
7.

Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.

Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P.

Blood. 2020 Mar 12;135(11):862-865. doi: 10.1182/blood.2019002920. No abstract available.

PMID:
31961918
8.

AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia.

Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, Keating MJ, Wierda W, Long JP, Bertilaccio MTS, Gandhi V.

Clin Cancer Res. 2020 Jan 14. pii: clincanres.1397.2019. doi: 10.1158/1078-0432.CCR-19-1397. [Epub ahead of print]

PMID:
31937611
9.

Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.

Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA.

Blood. 2020 Feb 13;135(7):510-513. doi: 10.1182/blood.2019003570. No abstract available.

PMID:
31895947
10.

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.

Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, Covey T, Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, O'Brien S, Furman RR.

Blood. 2019 Dec 26. pii: blood.2018884940. doi: 10.1182/blood.2018884940. [Epub ahead of print]

PMID:
31876911
11.

The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.

Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA.

Leukemia. 2019 Dec 20. doi: 10.1038/s41375-019-0682-7. [Epub ahead of print]

PMID:
31862959
12.

Evolving Strategies in First-Line Chronic Lymphocytic Leukemia: Is There a Role for Chemoimmunotherapy?

Brown JR, Wierda WG.

J Natl Compr Canc Netw. 2019 Nov;17(11.5):1408-1410. doi: 10.6004/jnccn.2019.5026.

PMID:
31766019
13.

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.

Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E.

Am J Hematol. 2020 Feb;95(2):144-150. doi: 10.1002/ajh.25671. Epub 2019 Nov 19.

PMID:
31682008
14.

STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.

Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z.

J Immunol. 2019 Dec 1;203(11):3078-3085. doi: 10.4049/jimmunol.1900389. Epub 2019 Oct 23.

PMID:
31645416
15.

First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL).

Alfayez M, Thakral B, Jain P, Ravandi F, Ferrajoli A, Jain N, Pemmaraju N, Wierda W, Kadia T.

Leuk Lymphoma. 2020 Feb;61(2):445-449. doi: 10.1080/10428194.2019.1660967. Epub 2019 Sep 30. No abstract available.

PMID:
31566032
16.

Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know.

Shah M, Rajha E, DiNardo C, Muckey E, Wierda WG, Yeung SJ.

Ann Emerg Med. 2020 Feb;75(2):264-286. doi: 10.1016/j.annemergmed.2019.07.015. Epub 2019 Sep 24. Review.

PMID:
31561995
17.

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S.

Blood. 2019 Nov 21;134(21):1811-1820. doi: 10.1182/blood.2019002118.

PMID:
31558467
18.

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.

Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, Neuberg D, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ.

Cancer Cell. 2019 Oct 14;36(4):369-384.e13. doi: 10.1016/j.ccell.2019.08.005. Epub 2019 Sep 19.

PMID:
31543463
19.

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.

Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG.

Blood. 2019 Nov 28;134(22):1951-1959. doi: 10.1182/blood.2019001077.

20.

Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia.

Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Scarfò L, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris-Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS.

Cancer Immunol Res. 2019 Dec;7(12):2036-2051. doi: 10.1158/2326-6066.CIR-19-0152. Epub 2019 Sep 17.

PMID:
31530560
21.

Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.

Jain N, Gandhi V, Wierda W.

N Engl J Med. 2019 Aug 22;381(8):789. doi: 10.1056/NEJMc1908754. No abstract available.

PMID:
31433937
22.

The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.

Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG.

Br J Haematol. 2019 Oct;187(1):e1-e4. doi: 10.1111/bjh.16117. Epub 2019 Jul 25. No abstract available.

PMID:
31344256
23.

Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.

Yalniz FF, Wierda WG.

Drugs. 2019 Aug;79(12):1287-1304. doi: 10.1007/s40265-019-01163-4. Review.

PMID:
31313099
24.

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.

Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC.

Blood. 2019 Aug 22;134(8):688-698. doi: 10.1182/blood.2019000490. Epub 2019 Jul 10.

25.

Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.

Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG.

Br J Haematol. 2019 Nov;187(3):307-318. doi: 10.1111/bjh.16042. Epub 2019 Jun 26.

PMID:
31243771
26.

Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?

Wierda WG.

Clin Adv Hematol Oncol. 2019 Apr;17(4):214-216. No abstract available.

PMID:
31188811
27.

Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells.

Chen LS, Keating MJ, Wierda WG, Gandhi V.

Leuk Lymphoma. 2019 Dec;60(12):3063-3066. doi: 10.1080/10428194.2019.1622098. Epub 2019 Jun 4. No abstract available.

PMID:
31161836
28.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W.

N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.

PMID:
31141631
29.

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.

Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A.

Blood Adv. 2019 May 14;3(9):1533-1539. doi: 10.1182/bloodadvances.2019031336.

30.

PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.

Cervantes-Gomez F, Stellrecht CM, Ayres ML, Keating MJ, Wierda WG, Gandhi V.

Oncotarget. 2019 Apr 19;10(29):2793-2809. doi: 10.18632/oncotarget.26876. eCollection 2019 Apr 19.

31.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF.

Blood. 2019 Jul 11;134(2):111-122. doi: 10.1182/blood.2018882555. Epub 2019 Apr 25.

32.

Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.

Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A.

J Geriatr Oncol. 2020 Jan;11(1):19-23. doi: 10.1016/j.jgo.2019.04.002. Epub 2019 Apr 18.

PMID:
31005650
33.

Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.

Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG.

Br J Haematol. 2019 Jun;185(5):852-864. doi: 10.1111/bjh.15877. Epub 2019 Mar 28.

PMID:
30924136
34.

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.

Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC.

Haematologica. 2019 Nov;104(11):2258-2264. doi: 10.3324/haematol.2018.207068. Epub 2019 Mar 28.

35.

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.

Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ.

Blood. 2019 Jun 27;133(26):2765-2775. doi: 10.1182/blood-2019-01-896290. Epub 2019 Mar 12.

36.

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE.

Int J Hematol. 2019 May;109(5):545-552. doi: 10.1007/s12185-019-02620-2. Epub 2019 Mar 4.

PMID:
30830579
37.

Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.

Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS.

Br J Haematol. 2019 Jul;186(1):184-188. doi: 10.1111/bjh.15791. Epub 2019 Feb 10. No abstract available.

PMID:
30740654
38.

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.

Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH.

Lancet Haematol. 2019 Feb;6(2):e100-e109. doi: 10.1016/S2352-3026(18)30216-3.

PMID:
30709431
39.

Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.

Chen R, Zhu M, Chaudhari RR, Robles O, Chen Y, Skillern W, Qin Q, Wierda WG, Zhang S, Hull KG, Romo D, Plunkett W.

Leukemia. 2019 Jul;33(7):1663-1674. doi: 10.1038/s41375-018-0364-x. Epub 2019 Jan 30.

PMID:
30700841
40.

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.

Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2019 Jan;17(1):12-20. doi: 10.6004/jnccn.2019.0002.

PMID:
30659125
41.

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.

Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ.

Blood. 2019 Mar 7;133(10):1011-1019. doi: 10.1182/blood-2018-10-879429. Epub 2018 Dec 7.

42.

Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.

Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ.

Cancer. 2019 Feb 15;125(4):559-574. doi: 10.1002/cncr.31831. Epub 2018 Dec 3.

43.

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.

Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H.

Lancet Haematol. 2018 Dec;5(12):e618-e627. doi: 10.1016/S2352-3026(18)30176-5.

PMID:
30501869
44.

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.

Wierda WG, Byrd JC, Davids MS, Furman RR, Cheson BD, Barr PM, Eradat H, Heffner L, Zhou L, Verdugo M, Potluri J, Choi M.

Br J Haematol. 2019 Jun;185(5):961-966. doi: 10.1111/bjh.15666. Epub 2018 Nov 27. No abstract available.

45.

Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation.

Boddu P, Thakral B, Alhuraiji A, Pemmaraju N, Kadia T, Ohanian M, Ravandi F, Jabbour E, Wierda W, Khoury JD, Jain N.

J Clin Pathol. 2019 Mar;72(3):251-257. doi: 10.1136/jclinpath-2018-205399. Epub 2018 Nov 22.

PMID:
30467242
46.

A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia.

Paul S, Jain N, Ferrajoli A, O'Brien S, Burger J, Keating M, Wierda W.

Br J Haematol. 2019 May;185(3):606-608. doi: 10.1111/bjh.15581. Epub 2018 Nov 8. No abstract available.

PMID:
30406944
47.

Cerebral edema secondary to chimeric antigen receptor T-cell immunotherapy.

Guha-Thakurta N, Wierda WG.

Neurology. 2018 Oct 30;91(18):843. doi: 10.1212/WNL.0000000000006436. No abstract available.

PMID:
30373920
48.

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.

Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M.

Front Oncol. 2018 Sep 24;8:369. doi: 10.3389/fonc.2018.00369. eCollection 2018.

49.

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.

Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, Kadia T, Cleeland C, Cortes JE, Kantarjian H.

Cancer Med. 2018 Nov;7(11):5457-5469. doi: 10.1002/cam4.1808. Epub 2018 Oct 14.

50.

Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.

Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM.

Cancer. 2018 Nov 1;124(21):4192-4201. doi: 10.1002/cncr.31658. Epub 2018 Oct 11.

Supplemental Content

Loading ...
Support Center